in contrast, fabulous growth companies like eog, noble and pioneer remind me of celgene, gilead and biogenastructure needed to refine the upstream products that's why i favor these more than exxon, shell and chevron. they can be takeover targets. this week i sat down with dan dickers, about the possibility of all things pioneer natural resources, permian play, actually getting a bid from one of these majors. he took it seriously. saying one of them will pay upwards of $40 billion for this $28 billion company. that's staggering. also a testament to how badly majors need growth. it's always possible the big dogs will split up, break themselves into more digestible pieces because i believe the parts are worth more than the whole. until then just like in the pharmaceutical world it's better to own the juniors than the majors. what a shame there isn't something in in between. bristol-myers of the oil world or johnson & johnson. i just don't see one out there that fits the bill. stick with eog, noble, my charitable trust favorite in the group, and pioneer. that true bow charged trio, oddly s whe

just a fascinating story of studying the history of celgene.reat guy, really fascinating company. >> indeet deed. good pick for the sunshine stock today. >> another pharma stock on the move, send it over to dominic chu for a market flash. >> check out shares of cancer drug company ariat pharmaceuticals up more than 30% after european regulators allowed the company to keep selling one of its leukemia drugs. the back story, the stock fell 44% back on october 31st after the fda here in the u.s. halted sales of that same drug because of treatment risks. shares of ariad around 380 right now but we're north of $20 the same time last year, so falling from grace but getting some of that back today. back over to you. >> certainly is. thank you very much. >>> well, happy holidays, everybody. because we found the cheapest gas in all america. sharon epperson has today's pump patrol. . >> the honeymoon may be over for low gas prices. today the national average is $3.24 a gallon. that's up 4 cents from a week ago. we're looking at refinery glitches in many p

like gilead, celgene, there they are, biogen, amgen, and alexion. you still own gilead. >> i have. haven't shaved any. i bought more. look, the stocks are not in bubble territory. they're the fastest -- among the fastest-growing stocks in the market, and the valuation for amgen, 15 times next year. gilead, over two years, 10 times. so with more and more people getting health care coverage, including the six that signed on to obama care, you'll see an explosion here in the earnings. >> the problem is, guys, you just can't -- in some respect, you can't help yourself if you want to take money off the table in these names, regardless of how well they've done -- >> take them off the -- take off the binary risk is. >> they've become big pharma names, honestly. when you look at the valuations, and in many cases returning shareholders through repurchasing or doing it through dividends, these are mature companies now, revenue growth, earnings growth. it's phenomenal. to your point, steve, when you look at where they're trading valuation-wise, celgene, amgen, they're not going down. >> it's

you should be in the googles, celgene. hain celestial.et, your suggestions on following foreign currency trading. go read confessions of a street addict and then tell me if you ever want to trade currency. and the answer is you won't. our next tweet comes from -- how do you always have so much energy. what's your secret? i think some is genetics and some is because i love what i do. now, a tweet from -- how does one find out the upgrades and downgrades before the opening bell. yahoo finance, the street.com. make sure that all those were in same game. still there. why not another tweet? it says what book would you suggest for newbies in understanding how to make the right choices on wall street. peter lynch, no longer, he's retired, who's just made me a fortune in my ira, and that is still the best investment book ever written. stick with cramer. [ male announcer ] this store knows how to handle a saturday crowd. ♪ [ male announcer ] the parking lot helps by letting us know who's coming. the carts keep everyone on the right track. the powe

expanding into even the best of the best, the celgenes, the gileads. i told you to wait until friday to sell that one. execute flawlessly. how is it that the imperfect execution of one biotech, and it didn't, wasn't -- it did what it was supposed to do, can somehow execute the entire group? because the sector pull in this cohort is extraordinary. today's precisely why i preach diversification so hard to you. when a less than fabulously better-than-expected quarter, yes, less than fabulously better than expected quarter gets reported for a stock that had run like nps, at which had been up 2,000% coming in, no, i'm sorry, had been up 200%, it's up huge, but 200% coming in for 2013, you get a wholesale slaughter. you can be the judge when we talk to francois nader tonight. he's the ceo of nps. and you can find out whether the collateral damage was a mistake or not. of course, drug stocks abhor a vacuum, and pharma was actually up today. yes, money switched from biotech to merck. then that's pioneer natural resources. the stock of this independent oil comp

now, celgene is breaking out to new highs. i follow because i believe it can earn $15 a share in 2017. yep, when you look at the out years, meaning more than just 2014, this company is even cheaper than pfizer, lily and bristol-myers. this stock jumped 20 points before the opening bell rang and continued to go higher because it got the nod for the new drug. biotech is a funny animal here. i don't know anyone who wasn't close to this company. and we said on air repeatedly that didn't think the approval would come. but as often the case it still prompted a great deal of buying, perhaps from short sellers who thought the sector after starting the year strong had run out of gas. and regeneron got a market for japan. that's going to continue to help the company maintain its streak. remember we had lynn on not that long ago. given there's a new mandate to reduce bad cholesterol, i think this could spur a huge 2014 if the company can get that accelerated approval from the fda. remember, from bio gen today, expected approvals can give

ce lchlt celgene, regeneron on the weak side, as well. strange tale of two retailers. biggest performer, best performer in the s&p 500, ralph lauren. they upped their guidance, the worst performer in the s&p, abercrombie & fitch. they cut their guidance completely different opposite ends of the spectrum. speaking of momentum names whole foods up 40%, one of the classic momentum names. in the after-hours com stores were below expectations. eps, comp store sales all below expectations lower guidance on metrics that is death for the big momentum traders. finally, maria, here it is the post for twitter. look, they just put up this symbol right here. this is where it's all going to happen tomorrow starting at 9:00 a.m. eastern time with a blow-by-blow description. >> we'll watch you, bob. thank you so much. as we await that check out bitcoins who would have trunkhunk thought it. mary telling us what is behind it. >> the virtual currency appears to get a lift from greater expectation and high-profile endorsements. new high coming a month after they were predicting its demise

celgene and gilead, they are fabulous leaders, by the way and they can hold on to the onslaught including this afternoon. power stocks are weaker throughout the day and it tells a good tale of men's and women's sales and they rallied when they pulled out. that's our sell-off. we have to go it a sell-off, where stocks and sectors run and there's another one heath up. the highly valued cloud-related technology groups run into it and it was cloudy and many were hit by meatballs made of the bear market. other less hot sectors, same with the transports where the airlines and the rails were smoking. >> all aboard! >> especially after the justice department folded the opposition to the u.s. airways and amr deal and then they cool with money going into other sectors. we had a decline in all retailers not that long ago led by macy's. a move so broad and powerful that it even took up walmart, which actually did disappoint. think of the power of that move. twitter's ipo inspired a rally in social media, but it's been heavy slogging since twitter broke the print price over the price where it opened.

take biotechs that are not so big as a celgene or gilead, like cubist pharmaceutical, cbst.ducts can destroy drug resistant infections including many of the diseases that lend -- well, that just end up to be cropping up in hospitals when you stay there. they save the health care system an enormous amount of money by reducing the number of people who get sick when they go to the hospital. cubist reported on october 22nd -- not a super bug, i hope. while the results seem disappointing, a slightly weaker than expected revenues, the real story is not the earnings, though, it's the acquisitions. the company's main drug, thermonuclear antibiotic goes off patent in 2018. they bought optimer in a deal that closed a week and a half ago and took over trius in a deal we learned about a few weeks after the ceo was on the show, 38.5% gain if you listen to that. it gives cubist an antibiotic for a nasty drug resistant infection common in hospitals and one that's already on the market. cubist has pulled back from its highs lately, but the stock is still up 33% from the last time i spoke to

celgene, i can come up with a $17 in 2015. that company is generating a huge amount of money. gilead, if the hep c pill works out, it's cheap. i think they're not absurdly valued. they're cheaper than pfizer on 2018 earnings. >> that echoes some of the action in clorox. kenny wanted to jump in. >> the point was made. we were talking about momentum names. a lot of names we saw under pressure today, they kind of follow the momentum. everyone jumps on when they want to take money out of it. like jim said if tomorrow they find a bid, they'll run back up on sentiment, the more trader type are the ones pushing those around. >> right, right. exactly. that's why you have to look at palo alto networks, just reported. it's hard to work and looking at stuff but this is a live show. that's part of the greatness of live, you're not looking up all the time. you're doing work. paola alto is up. that's cyber security. look at workday, now jumped three points. this is the reality. have you to deal with relate not yesterday. >> so true. jim cramer thank you so much for some of your time this af

the nasdaq dropping in large part due to the fall of apple tesla and celgene. apple down.3%, tesla down 15%. joe is chief market strategist with u.s. trust division of bank of america private wealth management. bob joins me here on the floor as well to talk about this market. joe, i'm going to start with you. as we move into the latter part of the year after such a spectacular performance by stocks, do you think the s&p 500's ten sectors will have a perfect ten all ending the year with double-digit gains? >> you know, sue, i do. it's very interesting, it hasn't happened since 1995. so even the so-called laggards, telecom, utilities, up 14, 15% and i think there's good liqu liquidity from the central banks around the world. a lot of retail investors coming back into equities. a host of reasons why i think we it continue to push higher across all sectors. >> now they've had pretty spectacular gains so far. how much more do you think is in this move and do you think that perhaps just a modest advance, that certainly would provide us with a very strong end of the y

gilead up along with celgene and other names. >> hedge funds have given up massive performance on thee. i'd say in the funds that i look at -- i look at a lot of them that have, say, 50% net long, they're down 10%, 20% in the short side. so you can't really go by this. a lot of the list is a safe list, where there's not a lot of beta, with the exception of gilead -- >> and no teslas or those names on there. before their gift helped preserve the point... .. before a credit solution was used to expand their business... before trusts were created for their grandkids' educations... they chose a partner to help manage their wealth... one whose insights, solutions, and approach have been relied on for over 200 years. that's the value of trusted connections. that's u.s. trust. >>> let's do our trader triple play where we find out what the floor traders are watching. todd at the cme, jeff grossman at the nymex and pete on the new york stock exchange. mr. grossman up first at the nymex what are energy traders watching today? >> we already saw it. we've been watching the inventory reports. last

nasdaq winners, biogen celgene, reagain ron. there are some red flags we talked about in the past. investors have pretty much shrugged off. one is the small cap market outperformance or underperformance versus the s&p 500. you can see here, there was a concern that small cap stocks might lead the market lower. we can see from the overall picture so far, we haven't seen that real underperformance with those stocks at all. that's a big move here for those particular stocks. that's one of the reasons why you're seeing this chart the way it is. it hasn't been a concern for investors at all. then we have what's been happening over the past week or month. a lot of people putting money into the small cap stocks. of course, the fed, a huge concern for a lot of investors here. a big question mark when will rates go higher and when will the taper come affect stocks? we have indication that markets think ben bernanke and janet yellen will keep the rates low until the economy recovers even more. maria, uncertainty is yes. but markets seem to be shrugging them off. >> thanks. want to bring in o

celje celgene. what's been up? costco, sysco, cvs. the otc markets sent me a note they're going to be reopening trading about now pending a notice from finra. those are the pink sheets. they've been out today on a system outage. i'll keep an eye on that. >>> i'm over here today. joining us now -- >> there you are. >> here i am. wherever i go. heather hughes from sun america funds is with us today. so is bill mcveil from the turner small cap growth fund. john smith from d.t. investment parters and our own rick santelli. welcome to everybody. heather hughes, we talk about this change in tone of the market. we've really felt in the last week or so the momentum stocks are going down. technology is taking a hit. even as the blue chips were going higher. what's going on? is there a rotation going on or what are you sensing here? >> yes. you're right. it's very interesting that the advisers we work with were saying look at the cyclical growth plays in industrials -- or technology, biotech got crushed yesterday. we're not seeing that happen.

guys tell you we're locking it in and share schit's innelinitz celgene. >> an employer coalition, overtar celebrating its tenth year. we're off and running on a tuesday. we're looking at 3996 in the nasdaq comp. we'll see if we bump up against that 4,000. >> your goal is a fantastic, fantastic piece in "usa today." they had two pieces about the nasdaq going higher, but they have a chart of what was leading the market. and, you know, it was cisco, david. cisco was 8% of the index back then. >> microsoft had an enormous market cap, 600 billion -- >> i remember infospace telling me they'd have the first trillion dollar market cap. >> there's still time. >> web fvan was going to take ot infospace. remember it was just don't sell us and then it became just don't sue us? >> that guy had the beret. >> joseph -- >> dignified fellow. >> those were good times, as long as you knew to sell right around now 13 years ago. let's take a look at men's wearhouse shares. we talked about it this morning of course. it is up sharply. we're going to speak later with larry graphstein, helps run m&a at ubs. 16